argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:35:28 2024-05-17 am EDT			5-day change	1st Jan Change
339.9 ^EUR	-1.45%		-2.30%	-1.05%

May. 17	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT
May. 15	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT

Argenx : argenx to Present at BofA Securities 2024 Health Care Conference

May 07, 2024 at 04:08 am EDT

argenx SE

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date07 may 2024 - 07:07

Statutory nameargenx SE

Titleargenx to Present at BofA Securities 2024 Health Care Conference

Previous result

Next result

Related downloads

202405070000000002_argenx to Present at BofA Securities 2024 Health Care Conference.pdf(opens in a new window)

Date last update: 07 May 2024

Attachments

Original Link
Permalink

Disclaimer

arGEN-X SE published this content on 07 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2024 08:07:05 UTC.

Latest news about argenx SE

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	May. 17	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	May. 15	MT
Transcript : Argenx SE Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM	May. 14
JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
Indexes already back on top	May. 10
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Fading Rate Cut Hopes	May. 09	MT
Transcript : Argenx SE, Q1 2024 Earnings Call, May 09, 2024	May. 09
Europe's STOXX 600 pauses after recent rally; BBVA weighs on Spain	May. 09	RE
Argenx Q1 Loss Widens, Total Operating Income Rises	May. 09	MT
U.S. Futures Edge Lower, European Stocks Mixed	May. 09	DJ
European shares pause after recent rally, BoE decision in focus	May. 09	RE
Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors	May. 08	CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	Apr. 16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	Mar. 27	CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	Mar. 26	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	Mar. 26	MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	Mar. 21	DJ

Chart argenx SE

Duration

Period

More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

339.9 EUR

Average target price

432.9 EUR

Spread / Average Target

+27.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	-1.05%	21.96B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B
LEGEND BIOTECH CORPORATION	-24.95%	8.23B

Bio Therapeutic Drugs